<div id="readability-page-1"><p>RiverFront Investment Group LLC raised its holdings in shares of  AbbVie Inc. (NYSE:ABBV - Free Report) by 41.7% in the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  owned 30,577 shares of the company's stock after purchasing an additional 9,005 shares during the quarter. RiverFront Investment Group LLC's holdings in AbbVie were worth $6,987,000 at the end of the most recent quarter.</p><ul><li>The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat</li></ul><p>A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in  AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares in the last quarter.  Legal &amp; General Group Plc grew its stake in  AbbVie by 4.3% during the 3rd quarter. Legal &amp; General Group Plc now owns 12,004,084 shares of the company's stock valued at $2,779,426,000 after purchasing an additional 493,420 shares in the last quarter.  Wellington Management Group LLP grew its stake in  AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter.  Amundi grew its stake in  AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter.  Finally, Ameriprise Financial Inc. grew its stake in  AbbVie by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock valued at $2,241,363,000 after purchasing an additional 408,426 shares in the last quarter. Institutional investors and hedge funds own  70.23% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In related news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own  0.06% of the company's stock. </p><h2>Analyst Ratings Changes</h2><ul><li>MarketBeat Week in Review – 04/27 - 05/01</li></ul><p>A number of equities research analysts have weighed in on the company. Citigroup lowered their price objective on AbbVie from $235.00 to $230.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, January 27th. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of AbbVie in a research note on Wednesday, January 21st. Evercore  set a $235.00 target price on AbbVie in a research report on Friday. Sanford C. Bernstein  reiterated a &#34;market perform&#34; rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Guggenheim  reiterated a &#34;buy&#34; rating and issued a $249.00 target price on shares of AbbVie in a research report on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued  a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $253.43.</p><p><b>Get Our Latest Stock Analysis on ABBV</b></p><h2>AbbVie Trading Up 0.1%</h2><ul><li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li></ul><p>Shares of ABBV opened at $210.54 on Monday. The firm has a market cap of $371.97 billion, a price-to-earnings ratio of 103.71, a PEG ratio of 0.73 and a beta of 0.32. The stock has a 50 day moving average of $210.27 and a 200-day moving average of $220.05. AbbVie Inc. has a 52 week low of $180.25 and a 52 week high of $244.81. </p><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business's revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 EPS.  On average, sell-side analysts predict that  AbbVie Inc. will post 14.3 earnings per share for the current fiscal year. </p><h2>AbbVie Announces Dividend</h2><p>The business also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie's payout ratio is currently 340.89%. </p><h2>Key AbbVie News</h2><p>Here are the key news stories impacting AbbVie this week:</p><ul>   <li><span>Positive Sentiment: </span>AbbVie’s Q1 results were supported by strong sales of <strong>Skyrizi</strong> and <strong>Rinvoq</strong>, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. <i></i><span>Article: How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?</span></li>   <li><span>Positive Sentiment: </span>Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably. <i></i><span>Article: AbbVie analyst estimate update</span></li>   <li><span>Positive Sentiment: </span>Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. <i></i><span>Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?</span></li> </ul><h2>AbbVie Profile</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Read More</h2><ul><li>Five stocks we like better than AbbVie</li><li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li><li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li><li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li><li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li></ul><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>RiverFront Investment Group LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 41.7% in Q4, owning 30,577 shares valued at $6.99 million. Other institutional investors, including Vanguard and Wellington Management, also raised their stakes. Insider selling occurred, with EVP Perry C. Siatis selling 22,381 shares. Analysts have mixed ratings on AbbVie, with a consensus rating of 'Moderate Buy' and an average target price of $253.43.</p>

Market Beat

Abbvie

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VG Health

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Legal & General Group Plc

Ameriprise Financial

Citigroup

Evercore

CITIGROUP INC 6.250 NON CUM SER II PFD WI

AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC